Luo X., Kranzler H., Lappalainen J., Rosenheck R., Charney D., Zuo L., Erdos J., van Kammen D.P., Gelernter J.

Am. J. Med. Genet. B Neuropsychiatr. Genet. 125B:25-30(2004) GAD 138622 · Mapped (4)
Not Associated with PSYCH: schizophrenia; cocaine abuse; Control:46/207 African-American (46) and European-American (207) control subjects;Case:70/206/90/118 subjects with schizophrenia (African-American (n=70) and European-American (206) and cocaine:dependence (African-American (n=90) and:European-American (118) GAD 138622

Edwards R.H., Ward M.R., Wu H., Medina C.A., Brose M.S., Volpe P., Nussen-Lee S., Haupt H.M., Martin A.M., Herlyn M. et al.

J. Med. Genet. 41:270-272(2004) GAD 138608 · Mapped (3)
Not Associated with CANCER: melanoma; GAD 138608

Kelemen L., James M., Spurdle A., Campbell I., Chang-Claude J., Peel D., Anton-Culver H., Berchuck A., Schildkraut J., Whittemore A. et al.

Gynecol. Oncol. 97:807-812(2005) GAD 138609 · Mapped (3)
Not Associated with CANCER: ovarian cancer; Case:383 low malignant potential ovarian cancer;Control:987:controls GAD 138609

Samowitz W.S., Sweeney C., Herrick J., Albertsen H., Levin T.R., Murtaugh M.A., Wolff R.K., Slattery M.L.

Cancer Res. 65:6063-6069(2005) GAD 138614 GeneRIF 673 · Mapped (3)
Associated with CANCER: colorectal cancer; GAD 138614 Observational study of gene-disease association. (HuGE Navigator) GeneRIF 673

Akslen L.A., Angelini S., Straume O., Bachmann I.M., Molven A., Hemminki K., Kumar R.

J. Invest. Dermatol. 125:312-317(2005) GAD 138615 GeneRIF 673 · Mapped (7)
Not Associated with CANCER: melanoma; GAD 138615 Observational study of gene-disease association. (HuGE Navigator); Although BRAF and NRAS mutations are likely to be important for the initiation and maintenance of some melanomas other factors might be more significant for proliferation and prognosis in subgroups of aggressive melanoma GeneRIF 673

Kim T.Y., Kim W.B., Song J.Y., Rhee Y.S., Gong G., Cho Y.M., Kim S.Y., Kim S.C., Hong S.J., Shong Y.K.

Clin. Endocrinol. (Oxf) 63:588-593(2005) GAD 138620 · Mapped (3)
Not Associated with CANCER: thryoid cancer; GAD 138620

Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W. et al.

Nature 417:949-954(2002) GeneRIF 673 · UniProtKB (1) · Mapped (2)
somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers GeneRIF 673

Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E.

Nature 418:934-934(2002) GeneRIF 673 · UniProtKB (1) · Mapped (2)
BRAF mutations in colorectal cancers occur only in tumours that do not carry mutations in a RAS gene known as KRAS and BRAF mutation is linked to the proficiency of these tumours in repairing mismatched bases in DNA GeneRIF 673

Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J. et al.

Nat. Genet. 33:19-20(2003) GeneRIF 673 · Mapped (3)
High frequency of BRAF mutations in nevi GeneRIF 673

Lang J., Boxer M., MacKie R.

Hum. Mutat. 21:327-330(2003) GeneRIF 673 · Mapped (3)
The V599E BRAF mutation appears to be a somatic mutation associated with melanoma development and/or progression in a proportion of affected individuals. GeneRIF 673

Singer G., Oldt R., Cohen Y., Wang B.G., Sidransky D., Kurman R.J., Shih I.e.M.

J. Natl. Cancer Inst. 95:484-486(2003) GeneRIF 673 · Mapped (11)
results demonstrate that the mutational status of BRAF and KRAS is distinctly different among histologic types of ovarian serous carcinoma occurring most frequently in invasive micropapillary serous carcinomas and its precursors serous borderline tumors GeneRIF 673

Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A.

Cancer Res. 63:1454-1457(2003) GeneRIF 673 · Mapped (19)
High prevalence of BRAF mutations in thyroid cancer is genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. GeneRIF 673

Cohen Y., Xing M., Mambo E., Guo Z., Wu G., Trink B., Beller U., Westra W.H., Ladenson P.W., Sidransky D.

J. Natl. Cancer Inst. 95:625-627(2003) GeneRIF 673 · Mapped (3)
activating BRAF mutations may be an important event in the development of papillary thyroid cancer GeneRIF 673

Yamaguchi T., Nagao S., Wallace D.P., Belibi F.A., Cowley B.D., Pelling J.C., Grantham J.J.

Kidney Int. 63:1983-1994(2003) GeneRIF 673 · Mapped (3)
cAMP activates ERK and increases proliferation of autosomal dominant polycystic kindey epithelial cells through the sequential phosphorylation of PKA B-Raf and MAPK in a pathway separate from the classical receptor tyrosine kinase cascade GeneRIF 673

Edmunds S.C., Cree I.A., Di Nicolantonio F., Hungerford J.L., Hurren J.S., Kelsell D.P.

Br. J. Cancer 88:1403-1405(2003) GeneRIF 673 · Mapped (3)
gene is mutated in skin melanoma but not in uveal melanomas GeneRIF 673

Laud K., Kannengiesser C., Avril M.F., Chompret A., Stoppa-Lyonnet D., Desjardins L., Eychene A., Demenais F., Lenoir G.M., Bressac-de Paillerets B.

Cancer Res. 63:3061-3065(2003) GeneRIF 673 · Mapped (3)
13 germline BRAF variants 4 of which were silent mutations in coding regions & 9 nucleotide substitutions in introns were found in melanoma patients and melanoma family but none appeared statistically likely to be a melanoma susceptibility gene. GeneRIF 673

Conner S.R., Scott G., Aplin A.E.

J. Biol. Chem. 278:34548-34554(2003) GeneRIF 673 · Mapped (16)
B-raf is involved in adhesion-independent ERK1/2 signaling in melanocytes GeneRIF 673

Cohen Y., Goldenberg-Cohen N., Parrella P., Chowers I., Merbs S.L., Pe'er J., Sidransky D.

Invest. Ophthalmol. Vis. Sci. 44:2876-2878(2003) GeneRIF 673 · Mapped (3)
Data suggest that BRAF T1796A activating mutation is not common in primary uveal melanoma. GeneRIF 673

Dillon T.J., Karpitski V., Wetzel S.A., Parker D.C., Shaw A.S., Stork P.J.

J. Biol. Chem. 278:35940-35949(2003) GeneRIF 673 · Mapped (8)
B-Raf has a role in extracellular signal-regulated kinase (ERK) signaling in T cells and prevents antigen-presenting cell-induced anergy GeneRIF 673

Weber A., Langhanki L., Sommerer F., Markwarth A., Wittekind C., Tannapfel A.

Oncogene 22:4757-4759(2003) GeneRIF 673 · Mapped (3)
BRAF has a role in in squamous cell carcinoma of the head and neck through uncommon mutations GeneRIF 673

Soares P., Trovisco V., Rocha A.S., Lima J., Castro P., Preto A., Maximo V., Botelho T., Seruca R., Sobrinho-Simoes M.

Oncogene 22:4578-4580(2003) GeneRIF 673 · Mapped (19)
The BRAF(V599E) mutation appears to be an alternative event to RET/PTC rearrangement rather than to RAS mutations which are rare in PTC. BRAF(V599E) may represent an alternative pathway to oncogenic MAPK activation in PTCs without RET/PTC activation. GeneRIF 673

Gemignani M.L., Schlaerth A.C., Bogomolniy F., Barakat R.R., Lin O., Soslow R., Venkatraman E., Boyd J.

Gynecol. Oncol. 90:378-381(2003) GeneRIF 673 · Mapped (3)
Mucinous ovarian cancers without a KRAS mutation have not sustained alternative activation of this signaling pathway through mutation of the BRAF oncogene. GeneRIF 673

Calipel A., Lefevre G., Pouponnot C., Mouriaux F., Eychene A., Mascarelli F.

J. Biol. Chem. 278:42409-42418(2003) GeneRIF 673 · Mapped (11)
3 cell lines derived from human choroidal melanoma express B-Raf containing the V599E mutation and showed a 10-fold increase in endogenous B-RafV599E kinase activity and a constitutive activation of the MEK/ERK pathway that is independent of Ras GeneRIF 673

Bonello L., Voena C., Ladetto M., Boccadoro M., Palestro G., Inghirami G., Chiarle R.

Leukemia 17:2238-2240(2003) GeneRIF 673 · Mapped (3)
Mutations are not detectable in plasma cell leukemia and multiple myeloma. GeneRIF 673

Namba H., Nakashima M., Hayashi T., Hayashida N., Maeda S., Rogounovitch T.I., Ohtsuru A., Saenko V.A., Kanematsu T., Yamashita S.

J. Clin. Endocrinol. Metab. 88:4393-4397(2003) GeneRIF 673 · Mapped (3)
mutation of BRAF gene could be a potentially useful marker of prognosis of patients with advanced thyroid cancers GeneRIF 673